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Abstract
Background: Aberrant expression of microRNAs, small non-coding RNA molecules that post-transcriptionally
repress gene expression, seems to be causatively linked to the pathogenesis of cancer. In this context, miR-21 was
found to be overexpressed in different human cancers (e.g. glioblastoma, breast cancer). In addition, it is thought
to be endowed with oncogenic properties due to its ability to negatively modulate the expression of tumor-
suppressor genes (e.g. PTEN) and to cause the reversion of malignant phenotype when knocked- down in several
tumor models. On the basis of these findings, miR-21 has been proposed as a widely exploitable cancer-related
target. However, scanty information is available concerning the relevance of miR-21 for prostate cancer. In the
present study, we investigated the role of miR-21 and its potential as a therapeutic target in two prostate cancer
cell lines, characterized by different miR-21 expression levels and PTEN gene status.
Results: We provide evidence that miR-21 knockdown in prostate cancer cells is not sufficient per se i) to affect the
proliferative and invasive potential or the chemo- and radiosensitivity profiles or ii) to modulate the expression of
the tumor-suppressors PTEN and Pdcd4, which in other tumor types were found to be regulated by miR-21. We
also show that miR-21 is not differently expressed in carcinomas and matched normal tissues obtained from 36
untreated prostate cancer patients subjected to radical prostatectomy.
Conclusions: Overall, our data suggest that miR-21 is not a central player in the onset of prostate cancer and that
its single hitting is not a valuable therapeutic strategy in the disease. This supports the notion that the oncogenic
properties of miR-21 could be cell and tissue dependent and that the potential role of a given miRNA as a
therapeutic target should be contextualized with respect to the disease.
Background
MicroRNAs (miRNAs) are small non-coding RNA mole-
cules that regulate gene expression by influencing the
stability or the translational efficiency of target mRNAs
[1]. Their tissue- and time-dependent expression influ-
ences protein production during distinct cellular pro-
cesses [1], and their aberrant expression is causative in
the pathogenesis of several diseases, including cancer
[2-4]. Many miRNAs have been identified as crucial
players in different human tumors [3].
miR-21 has high expression levels in glioblastoma [5],
breast cancer [6,7] and tumors of the gastrointestinal
tract [8-14] compared to normal tissues. In addition, it
has been reported to counteract the expression of
putative tumor-suppressive targets, such as phosphatase
and tensin homolog deleted on chromosome 10
(PTEN), programmed cell death 4 (Pdcd4), tropomyosin
1, maspin and reversion-inducing cysteine-rich protein
with kazal motifs [7,10-12,15-21]. On the basis of these
findings, miR-21 has been proposed to play a pivotal
role in the onset of several tumor types. Accordingly, its
antisense-mediated knockdown has been reported to
impair the growth, to induce apoptosis and to reduce
the migration and invasion of cancer cells highly expres-
sing miR-21 [5,10,20-27]. Altered miR-21 expression
levels have been also reported to affect the sensitivity to
different anticancer agents of cholangiocarcinoma and
pancreatic, non-small cell lung, glioma and ovarian can-
cer cells [11,28,29]. On the basis of these findings, miR-
21 has been referred to as an “oncomir” (i.e., a miRNA
with oncogenic properties), and the possibility to nega-
tively interfere with its expression or with its interaction
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with downstream targets has been suggested as a poten-
tial anticancer therapeutic approach.
Scanty information is available concerning the rele-
vance of miR-21 for prostate cancer (PCa). In this study,
we investigated the effects of miR-21 down-regulation in
PCa cell lines expressing it at high levels and character-
ized by a different status of PTEN, and provided evi-
dence that miR-21 knockdown is not sufficient per se to
significantly modify the proliferative potential and the
chemo- and radiosensitivity profiles of PCa cells. Our
findings suggest that the single hitting of miR-21 would
not be a valuable therapeutic strategy in this disease.
The hypothesis that miR-21 is not a major player in
PCa is also corroborated by the evidence that miR-21 is
not differently expressed in prostate carcinomas and
matched normal tissues obtained from 36 untreated
patients subjected to radical prostatectomy.
Our data support the notion that the oncogenic prop-
erties of miR-21 would be cell- and tissue-dependent
and that the potential role of a given miRNA as a thera-
peutic target should be contextualized with respect to
the disease.
Results and discussion
Several studies have demonstrated that miR-21 is an
oncomir with anti-proliferative and anti-apoptotic func-
tions [30]. In several cancer cell lines highly expressing
miR-21, its down-regulation by antisense oligomers
resulted in growth suppression, induction of apoptosis
and impairment of migration and invasion [5,10,20-27].
Scanty information has been obtained thus far regarding
whether or not miR-21 is involved in PCa. Through a
loss-of-function approach, we functionally investigated
the role of miR-21 and its potential as a therapeutic tar-
get in two experimental models of androgen-indepen-
dent PCa, DU145 and PC-3 cells. The two cell lines are
characterized by a different PTEN status (Figure 1A)
and distinct expression levels of miR-21 (Figure 1B). A
locked nucleic acid (LNA)-modified anti-miR-21 oligo-
mer (LNA21) was used to interfere with miR-21 func-
tion. The exposure of PCa cells to a carboxyfluorescein
(FAM)-labeled LNA21 resulted in a transfection effi-
ciency of almost 100%, as assessed by flow cytometry 24
h after transfection (Additional file 1, Figure S1).
Administration of LNA21 resulted in a nearly complete
reduction of free mature miR-21 abundance (Figure 1C),
as revealed by quantative reverse transcriptase-polymer-
ase chain reaction (qRT-PCR) and northern blotting
(Additional file 1, Supplementary Methods and Figure
S2). Such an effect was appreciable starting from day 1
after a 4-h transfection with the oligomer (quantification
of free miR-21 levels: 1.13 ± 0.1% and 1.42 ± 0.25%
compared to DU145 and PC-3 cells transfected with a
scrambled oligomer (LNAScr), respectively) and still
present at day 3 (3.80 ± 0.13% and 10.1 ± 0.85%) (Figure
1C). The impairment of miR-21 function – due to either
the degradation or the reduction of free miR-21 as a
consequence of LNA21-mediated “decoy effect” – failed
to affect the growth of PCa cells. In fact, the growth
curves of LNA21 transfectants were superimposable to
those of untreated or LNAScr-treated cells (Figure 2A).
In addition, when compared to untreated or LNAScr-
transfected cells, no changes in the number of migrating
cells were observed in DU145 or PC-3 cells transfected
with LNA21, as assessed by the Transwell assay at day 3
after transfection (Figure 2B). Again, when the assay was
performed in the presence of matrigel, as a surrogate of
the extracellular matrix, we could not detect any impair-
ment of the invading capabilities of PCa cells upon
interference with miR-21 function (Figure 2B). In con-
trast with our data, Li et al. [31] recently showed that a
2’-O-methyl-RNA oligomer against miR-21 significantly
reduced the migration and invasion capabilities of
DU145 and PC-3 cells. Such a discrepancy could reside
in the different chemistry of the anti-miR-21 oligomers
used. It has been demonstrated that the 2’-sugar and
backbone modifications significantly affect the ability of
antisense oligomers to interfere with the function and
activity of their targets. Specifically, it was found that at
concentrations higher than 30 nM some anti-miR-21-
modified oligomers, primarily 2’-O-methyl-phosphor-
othioates, had negative effects on cell behavior com-
pared to LNA oligomers [32-34], resulting in a
significant inhibition of cell proliferation independently
of target down-regulation. In this context, Li et al. [31]
did not evaluate the extent of miR-21 down-regulation
in their study. It has also been reported that the same
interactions influencing the tolerability of the chemical
modification of small interfering RNA (siRNA) passen-
ger strands hold true for modified anti-miRNA oligo-
mers. Specifically, using a model siRNA based on miR-
21 sequence, a set of modified passenger strands were
paired to an unmodified guide strand RNA and tested
for their ability to reduce the mRNA levels of PTEN – a
miR-21 target – in HeLa cells [32]. It has been found
that 2’-O-methyl-RNA oligomers, with either phospho-
diester or phosphorothioate backbones, were well toler-
ated as a PTEN siRNA passenger strand, paradoxically
triggering the activation of the RNA interference path-
way, and that their activity as siRNA was inversely cor-
related with their anti-miR-21 function [32]. When we
administered a 2’-O-methyl-modified anti-miR-21 oligo-
mer to DU145 cells, a ~50% inhibition of cell growth
was observed in spite of a less efficient down-regulation
of miR-21 (10-1-fold) compared to that obtained using
the LNA21 (10-2-fold) (Additional file 1, Figure S3), sug-
gesting the latter as a more specific tool to investigate
miR-21 function.
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In our hands, miR-21 knockdown did not trigger apop-
tosis as revealed by the lack of substantial caspase-3
activation (Figure 2C) in either cell line. However, a
~1.5-2-fold increase in caspase-3 catalytic activity was
appreciable in DU145 cells at day 2 after the transfec-
tion with LNA21 (Figure 2C), compared to untreated (P
= 0.03) or LNAScr-transfected cells (P = 0.11), which
disappeared one day later despite the persistent impair-
ment of miR-21 (Figure 2C). Such a temporary increase
in caspase-3 activity was likely insufficient to overcome
the threshold for the induction of apoptosis. In fact, we
observed a low percentage (<5% of the overall cell popu-
lation) of cells with an apoptotic nuclear morphology
after propidium iodide staining (data not shown). In
addition, we failed to detect a sub-G0/1 peak on DNA
plots at all time points considered (Figure 2D), except
for a pelting sub-G0/1 peak in DU145 cells at day 3 after
the transfection with either LNA21 or LNAScr (Figure
2D). These data would indicate that such a small frac-
tion of apoptotic cells reflects a stress response of cells
to treatment rather than being specifically related to
miR-21 depletion.
In some tumor models other than PCa, the overex-
pression of miR-21 has been associated with chemore-
sistance, and the modulation of its expression levels has
been proven to affect the activity of anticancer agents
[11,28,29]. Specifically, it has been shown that the over-
expression of miR-21 increased the resistance to gemci-
tabine of PANC-1 and SUIT-2 pancreatic cancer cells
[28] as well as of Mz-ChA-1 cholangiocarcinoma cells
[11], through the activation of PI-3 kinase and AKT/
mTOR signaling as a consequence of the suppression of
PTEN by miR-21 [11]. In addition, an increase in topo-
tecan-induced growth inhibition was appreciable in
MCF-7 breast cancer cells pre-incubated with an anti-
miR-21 oligonucleotide [29].
Based on these findings, we investigated whether miR-
21 down-regulation could be exploited as a strategy to
sensitize PCa cells to treatment with anticancer agents,
often inefficient for the clinical therapy of PCa [35].
LNA21-transfected DU145 cells were exposed to antic-
ancer drugs with different mechanisms of action (i.e.,
cisplatin and taxol) and ionizing radiation. Results indi-
cated that the impairment of miR-21 function did not
modify the chemosensitivity of DU145 or PC-3 cells,
since the growth curves of LNA21- transfected cells
were superimposable to those of untreated or LNAScr-
transfected cells, as evaluated at day 3 after the exposure
to cisplatin or taxol (Figure 3A). Accordingly, no differ-
ences in drug-induced apoptosis, evaluated as the per-
centage of propidium iodide-stained cells, were
appreciable in LNA21-transfected cells compared to
cells exposed to LNAScr (Figure 3B).
A recent study reported the effects of manipulating
miR-21 levels on drug resistance of cancer cell lines
characterized by different miR-21 basal expression levels
[29]. Upon ectopic expression of miR-21, an increased
resistance to doxorubicin was observed in A549 non-
small cell lung cancer and OVCAR3 ovarian cancer
cells, whereas an increased sensitivity to the same drug
was observed in SNB19 glioma cells [29]. Following
miR-21 knockdown, all three cancer cell lines showed
increased sensitivity to topotecan, whereas manipulating
the expression levels of miR-21 did not affect their sen-
sitivity to 10-hydroxycamptothecin [29]. These observa-
tions suggest that the effects arising from interference
with the expression of a specific miRNA could be
dependent on the cell model.
Figure 1 Characterization of PCa cells for miR-21 and PTEN expression. (A) RT-PCR and western immunoblotting, and (B) RNase protection
assay showing the basal expression levels of PTEN and miR-21 in DU145 and PC-3 cell lines. (C) qRT-PCR showing the down-modulation of free
miR-21 in DU145 (grey bars) and PC-3 cells (white bars) exposed to LNA21. Data are reported as relative quantity (RQ) of LNA21- over LNAScr-
treated cells and represent mean values ± SD of at least three independent determinations.
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Figure 2 Analysis of the effects of miR-21 knockdown on PCa cell behavior. (A) Growth curves of untreated (white triangle), LNAScr (black
circle)- or LNA21 (white circle)- transfected DU145 and PC-3 cells. (B) Analysis of the migrating (black bars) and invading (white bars) capabilities
of PCa cells (number of cells/mm2) at day 3, in untreated (UNT) and LNAScr- or LNA21-transfected cells. (C) Time-course determination of
caspase-3 catalytic activity in untreated (black bars) and LNAScr- (white bars) or LNA21-transfected (grey bars) cells. R.f.u.: relative fluorescence
units. (D) Time-course analysis of the cell cycle in UNT or oligomer-transfected PCa cells. Data represent mean values ± SD of at least three
independent experiments.
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Figure 3 Analysis of miR-21 knockdown on the chemosensitivity profiles of PCa cells. (A) Growth inhibition curves of untreated (black
triangle), LNAScr (black circle)- or LNA21 (white circle)-transfected PCa cells exposed to increasing concentrations of cisplatin or taxol. Data are
reported as percentage of growing cells compared to untreated controls and represent mean values ± SD of at least three independent
experiments. (B) Quantification of cells with an apoptotic nuclear morphology by propidium iodide staining of PCa cells transfected with LNAScr
(white bars) or LNA21 (grey bars) and exposed to IC50 of cisplatin or taxol. Data are reported as the average (± SD) of the percentage of
apoptotic cells in the overall cell population.
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No variation in the radiosensitivity profile of miR-21-
knocked-down PCa cells was observed on clonogenic
cell survival curves generated after the exposure to g-
radiation (2-8 Gy) with respect to those of controls (Fig-
ure 4A). However, when cultures were scored for the
presence of g-H2AX foci, a slight but significant
decrease (P = 0.05) in the percentage of cells harboring
DNA damage (>5 g-H2AX foci/nucleus) was appreciable
in miR-21-depleted cells (Figure 4B, C). This finding
would suggest that reducing miR-21 expression levels
could, at least in part, protect PCa cells from radiation
by limiting the induction of DNA damage, as already
described for other miRNAs in distinct cell systems.
Specifically, it has been shown that the in vitro down-
regulation of let-7 family members (i.e., let-7a and let-
7b) resulted in an increased radioresistance of A549
lung cancer cells [36]. Similarly, LNCaP cells knocked-
down for miR-521 showed a reduced sensitivity to radia-
tion, as a consequence of the up-regulation of Cockayne
syndrome protein A, a DNA repair factor targeted by
miR-521 [37].
Overall, our data suggest that miR-21 is not a major
player in PCa, as its single hitting is not enough to
counteract the proliferative potential of PCa cells or to
affect their sensitivity to anticancer drugs and radiation.
In addition, normal prostate RWPE-1 cells - which
express high levels of miR-21 (Additional file 1, Figure
S4) - did not show any biological response upon either
the depletion or up-modulation of the miRNA (Addi-
tional file 1, Figure S5). The negligible role of miR-21 in
PCa is also supported by expression data in experimen-
tal and clinical prostate models. Specifically, qRT-PCR
analysis revealed that androgen-dependent PCa cells
(LNCaP and VCaP) express markedly lower levels of
miR-21 than androgen-independent DU145 and PC-3
cells and that normal prostate RWPE-1 cells are charac-
terized by amounts of miR-21 similar to those of DU145
cells (Additional file 1, Figure S4). As regards the clini-
cal setting, we found that overall miR-21 expression
levels were similar in tumor and nonneoplastic tissue
specimens (average RQ 0.23 ± 0.21 and 0.24 ± 0.35,
respectively;P = 0.86) obtained from 36 untreated
patients subjected to radical prostatectomy (Figure 5A,
top). In addition, miR-21 was not consistently up-regu-
lated in carcinomas compared to the matched normal
tissues from each patient (Figure 5A, bottom).
No significant differences in miR-21 expression were
observed as a function of nodal status (average RQ 0.243
± 0.223 and 0.168 ± 0.143 in localized (N-) vs. local-
regionally disseminated (N+) disease; P = 0.35), extrapro-
static extension of the disease (0.219 ± 0.128 and 0.245 ±
0.272 in negative vs. positive specimens; P = 0.730), or
Gleason score (0.200 ± 0.101 and 0.274 ± 0.272 in speci-
mens scored <7 vs. ≥ 7; P = 0.45) (Figure 5B).
miR-21 was proposed to be one of the six miRNAs
whose overexpression represents the signature for solid
tumors [38]. However, survey of available data on
miRNA expression in PCa clinical specimens showed it
was not differently expressed in tumor and normal pros-
tate tissues [39-42] or in localized and metastatic PCa
[43] in 5 out of 6 studies [38-43] (Table 1 and Addi-
tional file 1, Supplementary Methods). This suggests
that miR-21 up- modulation is not a common or rele-
vant event in prostate tumorigenesis.
The peculiar aspect that makes a miRNA a sophisti-
cated engine to finely tune the expression of genes
resides in its possibility to simultaneously target several
cellular factors [2,3]. Consequently, the function of a
given miRNA strictly depends on the cell phenotype
and, therefore, on the presence of its targets in the tis-
sue where it is expressed. In this context, we wondered
whether the absence of any evident effect on miR-21
knockdown could rely on the lack of its key downstream
targets or in a reduced ability to suppress them in PCa
cells. DU145 cells inherently express PTEN (Figure 1A),
a direct target of miR-21 as predicted by distinct target
prediction analysis softwares (e.g., miRanda and RNAhy-
brid) and validated by functional analyses [7,11,15]. Our
data showed that upon exposure to LNA21, the expres-
sion levels of PTEN (mRNA and protein) were not sub-
stantially altered, compared to untreated or LNAScr-
transfected cells (Figure 5C). This finding suggests that
miR-21 is not involved in the regulation of PTEN
expression in DU145 cells.
To verify such a hypothesis, we wondered whether in
a clinical setting there was an inverse correlation
between miR-21 expression and that of PTEN, as would
be expected in the presence of an intimately related
miRNA and target gene pair. The analysis of PTEN and
miR-21 expression carried out in a subset (n = 29) of
clinical specimens, for which residual RNA was avail-
able, did not show any significant correlation (rS =
-0.00717; P = 0.957) in the expression levels of the two
factors (Figure 5D). It cannot be excluded that the miR-
21 responsive elements in the 3’-untranslated region
(UTR) of PTEN could be inaccessible in PCa cells as a
consequence of folding constraints or mutations that
disable the interaction with miR-21, thus enabling the
gene to evade regulation by the miRNA.
It is noteworthy that the number and nature of speci-
fic miRNA target sequences within the 3’-UTR of
mRNAs can significantly affect the sensitivity of a target
to the action of a related miRNA. In this context, it has
been reported that single nucleotide polymorphisms in
miRNA binding sites, which hamper the miRNA-
mediated regulation of gene expression, can be asso-
ciated to cancer predisposition [44]. Specifically, a var-
iant allele at a single nucleotide polymorphism in a let-7
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Figure 4 Analysis of miR-21 knockdown on the radiosensitivity profiles of PCa cells. (A) Clonogenic survival curves of untreated (black
triangle), LNAScr (black circle)- or LNA21 (white circle)-transfected cells calculated on day 12 after exposure to increasing doses (2-8 Gy) of g-
radiation. Data shown on the plots represent the inter-experiment averages (± SD) calculated from at least three intra-experiment averages. (B)
Representative immunofluorescence analysis of g- H2AX induction in LNAScr- or LNA21-treated DU145 cells exposed to g- radiation (4 Gy). Nuclei
were counterstained with 4’,6-diamidino-2-phenylindole. Scale bar: 10 μm. Magnification: × 40. NR, no radiation. (C) Quantification of g- H2AX
foci in DU145 (top panel) and PC-3 cells (bottom panel). Data are reported as percentage of g- H2AX-positive cells in the overall cell population
(mean values ± SD).
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Figure 5 miR-21 expression in carcinomas and normal prostate tissues. (A) Quantification of miR-21 expression levels (top panel) in
carcinomas and matched normal tissues obtained from 36 patients subjected to radical prostatectomy. Data are reported as RQ of miR-21
expression with respect to an internal calibrator (RWPE-1). Analysis of miR-21 expression (bottom panel) reported as Log10 of the ratio tumor/
matched normal tissue for each patient (RQtumor/RQnormal). (B) miR-21 expression levels (average RQ ± SD) as a function of nodal status,
extraprostatic extension (EPE) of the disease and Gleason score. (C) Representative RT-PCR and western immunoblotting showing the expression
of miR-21 validated target genes in untreated and LNAScr- or LNA21-treated DU145 cells, at days 2 and 3 after transfection. (D) Scatterplot
showing the lack of a correlation between RQ expression values of miR-21 and PTEN mRNA in clinical specimens.
Folini et al. Molecular Cancer 2010, 9:12
http://www.molecular-cancer.com/content/9/1/12
Page 8 of 12
complementary site in the 3’-UTR of k-ras was found to
be associated with a 1.4- to 2.3- fold increased risk for
non-small-cell lung cancer among moderate smokers
[44]. To our knowledge, the occurrence of single
nucleotide polymorphisms in the 3’-UTR of miR-21 tar-
gets has not been described thus far in PCa cells.
Consistent with the inverse relationship between a
miRNA and its target gene, a slight up-modulation of
Pdcd4 protein – a validated target of miR-21 in different
cancer experimental models [12,16-19,27] – was appreci-
able 3 days after the exposure of DU145 cells to LNA21
compared to untreated or LNAScr-transfected cells (Fig-
ure 5C). However, Pdcd4 downstream signaling pathway
[45] was not substantially impaired upon miR-21 down-
modulation, as indicated by the comparable levels of
p34cdc2 in the different cultures (Figure 5C), which was
reflected by the lack of cell cycle perturbations (Figure
2D). Similarly, no change in the expression of Pdcd4 or
p34cdc2 was appreciable in the PTEN-negative PC-3 cells
upon miR-21 depletion (Additional file 1, Figure S6),
although in these cells we failed to properly detect Pdcd4
protein, perhaps due to the fact that its expression levels
are below the threshold for detection by western blotting.
These findings were also corroborated by the luciferase
gene reporter assay, in which a slight but not statistically
significant down-modulation of luciferase activity was
observed in DU145 and PC-3 cells co-transfected with
Luc-Pdcd4WT plasmid (harboring the 3’-UTR of Pdcd4
[27]) and a synthetic precursor of miR-21, compared to a
control oligomer (Additional file 1, Figure S7). Moreover,
no perturbations of luciferase activity were observed in
cells exposed to either LNA21 or LNAScr (Additional file
1, Figure S7).
Overall, our findings indicate that the persistent and
marked depletion of miR-21 in PCa cells does not result
in an efficient modulation of the downstream factors
that, in other tumor histotypes, have been associated to
its oncogenic functions, thus explaining the reason for
its failure to counteract PCa. Such a scenario could
depend on the fact that those factors (e.g., PTEN or
Pdcd4) undergo multiple hitting by distinct miRNAs,
making their expression levels dependent on the miR-
NAs “dowry” of a cell. In addition, an imbalance in
favor of the deregulated expression of other pro-survival
and anti-apoptotic miRNAs could be responsible for the
ability of PCa cells to overcome the antitumor pheno-
type that in other tumor experimental models arises fol-
lowing miR-21 knockdown [5,10,20-27]. In this context,
it would be useful to investigate whether the simulta-
neous down-regulation of miR-21 and other still uniden-
tified miRNAs, converging on miR-21 target genes,
synergizes in counteracting the proliferative potential of
PCa cells. Such a strategy could represent a suitable
multi-target therapeutic approach to achieve sponta-
neous or treatment-induced PCa cell death.
Conclusions
We have provided compelling evidence that miR-21 is
not per se a central player in the onset of PCa and that
its single hitting does not represent a valuable therapeu-
tic intervention in such a disease. Our findings contri-
bute to support the notion that the oncogenic
properties of miR-21 - and generally speaking that of
any miRNA- could be cell and tissue dependent and
that its potential role as a biomarker or therapeutic tar-
get should be put in the context of a given disease.
On the basis of available data, it is clear that we are
still far from the precise identification of miRNAs
potentially relevant for the initiation and progression of
PCa. Even if further investigations are warranted to
unequivocally identify PCa-associated miRNAs, there is
evidence that deregulated expression of other miRNAs,
instead of miR-21, could represent a prominent event
responsible for the onset of the disease [46-48]. Such
Table 1 miR-21 expression in human prostate1
Study miR-21
expression2
Case series Analytical method
Volinia et
al. [38]
↑ 56 PCa; 7 normal prostate tissues from non-cancer individuals In-house microchip oligonucleotide microarray
Lu et al.
[39]
= 6 PCa; 8 normal prostate tissues Bead-based flow cytometry detection system
Porkka et
al. [40]
= 9 PCa; 4 benign prostatic hyperplasias In-house oligonucleotide microarray
Ozen et al.
[41]
= 16 PCa; 10 benign prostatic hyperplasias miRvana miRNA bioarrays
Ambs et al.
[42]
= 60 macrodissected PCa; 16 surrounding non-tumor prostate
tissues
microRNA microarray (Ohio State University
Comprehensive Cancer Center, Version 3.0)
Leite et al.
[43]
= 18 localized high-grade PCa from radical prostatectomies; 4
metastatic, androgen-independent PCa
TaqMan miRNA qRT-PCR assay
1The analysis was carried out as reported in Additional file 1, Supplementary Methods.
2Up-modulation (↑) or no differential expression (=) of miR-21 in prostate tumors vs. control tissue used in the study (i.e., normal prostate or benign prostatic
hyperplasia or localized high-grade PCa).
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evidence puts in the limelight the opportunity to suc-
cessfully exploit these “alternative” miRNAs as new bio-
markers for diagnosis or prognostication as well as
suitable tools or targets for future therapeutic interven-
tions in PCa.
Methods
Experimental models
Human PCa cell lines (DU145 and PC-3) were obtained
from American Type Culture Collection (Rockville MD).
Cells were resuscitated soon after arrival, cultured in
RPMI 1640 medium with 10% fetal calf serum and
maintained in 5% CO2 at 37°C in separate incubators.
Carcinoma and matched normal prostate tissues were
obtained, with appropriate informed consent and Insti-
tutional Review Board approval, from 36 untreated PCa
patients subjected to radical prostatectomy. Freshly fro-
zen surgical blocks, stored in the Institutional Frozen
Tumor Bank, were carefully dissected by the pathologist
using hematoxylin-eosin-stained sections as a template
to identify areas containing at least 70% of tumor or
normal cells.
miRNA and gene expression analysis
Total RNA was isolated from cell cultures and clinical
samples through Trizol reagent (Invitrogen, San Giu-
liano Milanese, Italy) as previously described [49]. miR-
21 expression levels were evaluated by RNase protection
assay as described in Additional file 1, Supplementary
Methods and Table S1. For gene expression studies,
cDNA was randomly primed from 0.5 μg RNA and
amplified using the GeneAmp RNA PCR Core kit
(Applied Biosystems, Monza, Italy). b-actin was used as
PCR internal control.
Quantification of mature miR-21 and mRNA expres-
sion levels was assessed by qRT-PCR using specific Taq-
Man® Assays (Applied Biosystems). Amplifications were
run on the 7900HT Fast Real-Time PCR System. Data
were analyzed by SDS 2.2.2 software (Applied Biosys-
tems) and reported as relative quantity (RQ) with
respect to a calibrator sample using the 2-ΔΔCt method.
U6 snRNA and RNaseP were used as normalizers.
All primer sets used are listed in Additional file 1,
Tables S2-S3.
Cell-based experiments
Cells seeded at the appropriate density were transfected
for 4 h at 37°C with 100 nM anti-miR-21 (LNA21) or
scramble (LNAScr) miRCURY™ knockdown probes (Exi-
qon, Vedbaek, Denmark) using Lipofectamine2000™
(Invitrogen), according to the manufacturer’s instruc-
tions. Cell growth was evaluated at days 1-3 after trans-
fection by counting cells in a particle counter (Coulter
Counter, Beckman Coulter, Fullerton, CA).
For the migration assay, cells were transferred to the
upper chamber (2 × 105 cells/well) of 24-well Transwell
plates (Costar, Corning Incorporated, Corning, NY) in
serum-free medium and chemoattractant (i.e., condi-
tioned medium obtained by incubating growing cells in
a medium without serum for 24 h) was added to the
lower chamber. After a 5-h incubation at 37°C, cells in
the upper side were cleaned off and filters were fixed in
99% ethanol and stained with a solution of 0.4% sulfor-
hodamine B in 1% acetic acid. Migrated cells were
counted under a microscope. The same procedure was
used for invasion assay, except that cells were seeded at
3 × 105 cells/well, Transwell chambers coated with 12.5
μg of Matrigel/well (BD Biosciences, San Jose, CA), and
samples processed after a 24-h incubation.
Caspase-3 catalytic activity was measured using the
APOPCYTO/caspase-3 assay kit (MBL International,
Naka-ku Nagoya, Japan). Total protein extracts and the
specific fluorogenic substrate N-acetyl-Asp-Glu-Val-
Asp-pNA (DEVD-pNA) were mixed and incubated for
1 h at 37°C, and the hydrolysis of DEVD-pNA was
monitored by spectrofluorometry at l460 nm. The pre-
sence of a sub-G1 peak suggestive of apoptosis [50]
was evaluated by a FACScan flow cytometer (Becton
Dickinson, Franklin Lake, NJ) on cells fixed in pre-
cooled 70% ethanol and stained with a solution con-
taining 50 μg/ml propidium iodide, 50 mg/ml RNase
and 0.05% Nonidet P40 for 30 min at 4°C. A minimum
of 3 × 104 events was measured for each sample, and
the sub-G1 peak was detected on DNA plots by Cell-
Quest software according to the Modfit model (Becton
Dickinson). An aliquot of propidium iodide-stained
cells was spotted onto glass slides and examined under
a fluorescence microscope for the presence of nuclei
with an apoptotic morphology. The percentage of
apoptotic cells was determined by scoring at least 500
cells for each sample.
For the evaluation of chemo- and radiosensitivity, cell
growth analysis and clonogenic assay were performed,
respectively. For the chemosensitivity assay, the growth
of LNA-transfected PCa cells was evaluated by cell
counting at day 3 after a 1-h or 24-h exposure to
increasing concentrations of cisplatin (0-18 μM) or taxol
(0-10 nM), respectively. For irradiation experiments, one
day after exposure to LNAs, exponentially growing cells
were harvested and irradiated (2-8 Gy) at room tem-
perature using a 137Cs g irradiator (IBL-437) at a dose
rate of 7.2 Gy per min, plated at appropriate concentra-
tions in plastic dishes, and incubated at 37°C for 12
days. Colonies were stained with crystal violet in 70%
ethanol and counted under the microscope. The colony-
forming efficiency was calculated from the number of
colonies (consisting of at least 50 cells) counted and the
number of morphologically intact single cells seeded,
and the surviving fractions of treated cells relative to
non-irradiated cells were determined.
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Immunoblotting and immunofluorescence analyses
For immunoblotting, proteins were fractioned by SDS-
PAGE and transferred onto Hybond nitrocellulose mem-
branes (GE Healthcare, Amersham, UK). Filters were
blocked in PBS-Tween-20 in 5% skim milk and probed
with antibodies raised against PTEN (Abcam, Cam-
bridge, UK), Pdcd4 (Abcam), and p34cdc2 (Santa Cruz
Biotechnology, Santa Cruz, CA), which were visualized
by a SuperSignal® West PICO chemiluminescent detec-
tion system (Thermo Scientific, Rockford, IL). b-actin
was used as equal protein loading control.
For immunofluorescence analyses, cells grown on glass
coverslips were fixed with 4% formaldehyde and probed
with primary anti-g-H2AX (Abcam) and secondary
AlexaFluor594 (Invitrogen) antibodies. Images were
acquired by a Nikon Eclipse E600 microscope using
ACT-1 software (Nikon Corporation, Japan) and pro-
cessed with Adobe Photoshop Image Reader 7.0.
Statistical analyses
Two-sided Student’s t test was used to analyze the dif-
ferences in miR-21 expression levels, cell growth, migra-
tion, invasion, caspase-3 activity and chemo- and
radiosensitivity profiles. Spearman’s correlation coeffi-
cient (rS) with associated P value was calculated for
PTEN mRNA and miR-21 expression in clinical sam-
ples. Two-tailed P values < 0.05 were considered statisti-
cally significant.
Additional file 1: Supplementary Information. Supplementary
methods, tables and figures.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1476-4598-9-12-
S1.PDF ]
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